Redeye shares its preview of Physitrack’s Q2 2026 results, ahead of the official report on 21 July. While recent newsflow on new agreements and the Remote Therapeutic Monitoring (RTM) launch is encouraging, the timing suggests limited impact on Q2 figures. We expect the report's main highlights to be steady topline growth, though margins will likely compress somewhat.
LÄS MER
